Shirweynihii 18aad ee Adduunka ee Kansarka mindhicirka, wejiga I ee daraasad caafimaad ayaa muujisay in anti-PD-L1 immunotherapy oo ay weheliso MEK inhibitors ay si wax ku ool ah u daweyn karto microsatellite xasilloon oo kansarka mindhicirka.
Baaraha hogaamiyaha daraasadan, Johanna Bendell oo ka tirsan machadka Cancer Institute ee Sarah Cannon, ayaa tilmaamtay: Ilaa iyo hada, difaaca jirka ayaa kaliya waxtar u leh bukaanada leh microsatelite sare oo aan xasilloonayn kansarka mindhicirka, bukaanadan noocan ahna waxay gaarayaan 5% oo kaliya dadka.
Kansarka mindhicirka ee aan xasilloonayn microsatellite aadka u sarreeya ayaa leh tiro badan oo isbeddello ah oo sidaas darteed ka jawaabaya anti-PD-1 / PD-L1 immunotherapy. Si kastaba ha ahaatee, qiyaastii 95% bukaanada qaba kansarka mindhicirka dheef-shiid kiimikaadka ayaa leh microsatellite foci deggan. Ilaa hadda, qaybtan bukaannada ayaa si dhib leh uga jawaabtay daaweynta tallaalka.
Daraasadaha takhasuska hore waxay soo jeedinayaan in ka-hortagayaasha 'MEK' ay ka dhigi karaan burooyinka kuwo aad ugu nugul difaaca jirka. Farsamaynta gaarka ah waxay noqon kartaa inay kordhiso tirada unugyada difaaca jirka ee firfircoon (sida unugyada wanaagsan ee CD8) ee burooyinka oo ay kordhiyaan muujinta waxyaabaha firfircoonida nidaamka difaaca jirka.
Natiijooyinka daraasadda ayaa muujisay in daraasadda caafimaad ee Wajiga I b loo adeegsaday daawada loo yaqaan 'MEK inhibitor' Cobimetinib si loogu daaweeyo 23 bukaan oo qaba kansarka mindhicirka la daweeyay iyadoo loo eegayo qiyaasta kor u kaca. (Q3W), bukaanada badankood way u dulqaadan karaan qiyaaso badan waxaana lagu daaweeyaa 800 mg oo ah PD-L1 inhibitor Atezolizumab (duritaanka xididka, Q2W).
Daaweynta la-socoshada, cilmi-baarayaashu waxay arkeen in bukaanada 4 (17%) ay yareeyeen buro ugu yaraan 30%, iyo bukaanada 5 (22%) ay qabaan cudur deggan. Waqtiga saamaxa ee joogtada ahi wuxuu ka badan yahay 4 ~ 15 bilood. Marka la eego xogta hadda jirta, 2 ka mid ah 4-tii bukaan ee qayb ahaan laga soo daayay waxay heleen gaabin joogto ah. Bukaannada qaba qeyb ka-cafiska, 3 xaaladood waxay ahaayeen mikrosatellite deggan ama xasillooni darro heerkeedu hooseeyo, iyo 1 kiis oo aan la garanayn xaaladda mikrosatellite-ka. Bukaannada lagu daro daraasadda, ma jirin kiisas microsatellites aad u deggan.
Intaa waxaa sii dheer, heerka aasaasiga ah ee PD-L1 ma saameynayo ka-dhaafitaanka cudurrada, daawooyinka isku-dhafan ayaa si wanaagsan loo dulqaatay, mana jiraan dhacdooyin khatar ah oo daaweyn la xiriira.
Bendell wuxuu ku soo gabagabeeyey: "Natiijooyinka daraasadda waxay la jaanqaadayaan mala-awaalka daaweynta isku dhafan, taasoo sidoo kale siinaysa boqolkiiba 95% bukaannada kansarka malawadka ah fursad ay ku helaan tallaalka difaaca jirka." Baadhuhu wuxuu bilaabayaa waji III daraasad caafimaad, qorshaynta inuu kooxda galo waa adagtahay Daaweynta metastatic kansarka mindhicirka, isbarbar dhig waxtarka daaweynta isku dhafan ee nidaamyada caadiga ah.
